DDR Combination Therapies Infographic
As the DDR space seeks to find efficacious combinations whilst minimising toxicity to patients, combination therapies are becoming a key topic of discussion. This infographic looks at current combination therapies being evaluated in the clinic by target, disease indication and more, with a particular focus on ATR inhibitors and DDRi’s in combination with ADC’s.
Infographic highlights include:
- An overview of the DDR combination therapy landscape
- A look at ATRi’s and ICM’S
- A focus on the emerging combination strategy of DDRi’s and ADC’S
- A summary of the current landscape and key learnings
You May Also Be Interested In…
What is Beacon?
Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.
Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.
This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.
We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!
